Congressman tells AG Garland that Esformes case is ‘political’ … FHCA unveils 2023 legislative priorities … Medicare advisers suggest tweak to coverage process for Alzheimer’s drugs … Schumer...
Bipartisan group pushes CMS to expand coverage for Alzheimer’s treatments
By
Kimberly Bonvissuto
Feb 21, 2023
Access to federally approved monoclonal antibody and other disease-modifying therapies for Alzheimer’s disease will be “extremely limited” unless the Centers for Medicare & Medicaid Services reconsiders...
Focus on briefs: Dementia
Feb 01, 2023
Alzheimer’s blood test, Aducanumab approval issues, Medicare coverage of brain scans that diagnose dementia, Some at higher risk for Alzheimer’s
Social isolation contributes to increased likelihood of dementia: study
By
Kimberly Bonvissuto
Jan 11, 2023
Social isolation is common among older adults in the United States — experienced by one in four of them — and increases the likelihood of developing dementia, according to the results of a new study.
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.
PTSD, TBI interact with APOE ε4 to raise Alzheimer, dementia risk
Jan 06, 2023
Significant additive APOE ε4 interactions were seen with PTSD and TBI in veterans of European ancestry.
Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
Senior living celebrates ‘big wins’ in proposed $1.7 trillion omnibus package
By
Kimberly Bonvissuto
Dec 21, 2022
Senior living advocates are claiming “major victories” for the industry following the release of the proposed $1.7 trillion congressional year-end spending bill on Monday.
More news for Wednesday, Dec. 7
By
Kimberly Bonvissuto
Dec 07, 2022
Operating environment for life plan communities expected to deteriorate in 2023: Fitch … UK on cusp of personalized Alzheimer’s therapies … Older adults stress less than twentysomethings: study …...
Study explores impact of FDA approval of aducanumab on trial participation
Dec 06, 2022
Individuals who were independently aware of the FDA decision demonstrated a reduced willingness to participate.